sanofi-aventis, Viale Luigi Bodio, 37/b – 20158 Milano (MI)
(from 01/01/2005 to 31/12/2006 = 2 years)
In the TA (Therapeutic Area) «oncology»:
- marketing strategy development (and tactical implementation) for the brand ELOXATIN™ (oxaliplatin), an antineoplastic drug (anti-cancer medicine) used for the treatment of colorectal cancer (approved indication) and other types of gastrointestinal cancers
- post-patent strategy for the brand name ELOXATIN™ (oxaliplatin)
- indication management of TAXOTERE™ (docetaxel) for the treatment of advanced gastric cancer
